MedTrace Logo

Glucocorticoids Promote Osteoclast Survival

NCT00572299 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2011-08-30

No results posted yet for this study

Summary

The purpose of this study is to determine the difference in response to bisphosphonate therapy in patients receiving excess glucocorticoids compared to patients with postmenopausal or male osteoporosis. Bisphosphonates are approved by the FDA for the treatment of postmenopausal women and osteoporotic men who are at high risk of fracture and in men and women with excess glucocorticoid administration.

Conditions

Interventions

DRUG

alendronate

70 mg of alendronate orally per week for at least three months in patients receiving at least 10 mg/day or oral prednisone for at least three months

Sponsors & Collaborators

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Jimmie L Valentine · IRB at UAMS

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00572299 on ClinicalTrials.gov